Efficacy and safety of olodaterol once daily delivered via Respimat(®) in patients with GOLD 2–4 COPD: results from two replicate 48-week studies

BACKGROUND: Olodaterol is a long-acting β(2)-agonist with a 24-hour bronchodilator profile. Two replicate, randomized, double-blind, placebo-controlled, parallel-group, Phase III trials were performed as part of a comprehensive clinical program to investigate the long-term safety and efficacy of olo...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Ferguson, Gary T, Feldman, Gregory J, Hofbauer, Peter, Hamilton, Alan, Allen, Lisa, Korducki, Lawrence, Sachs, Paul
Формат: Artigo
Язык:Inglês
Опубликовано: Dove Medical Press 2014
Предметы:
Original Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4064950/
https://ncbi.nlm.nih.gov/pubmed/24966672
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S61717
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы